Recent years have shown a rise in development across the generic and biosimilar industries, as many blockbuster products near the end of their patents. The need to expand the reach of RandD programs has driven major new investments in co-development, strategic alliances, licensing and acquisitions, with big pharmaceutical companies scrambling to maintain their strongholds on specific therapeutic areas. This has increased the need for a robust due diligence process across all functions, as companies look to external targets as a means of supplementing pipelines and bolstering their product portfolios.
The 3rd Due Diligence Summit for Life Sciences will provide an overview of the proven strategies and insights of due diligence leaders from medical device, biotechnology and pharmaceutical companies and discuss how best to maneuver the rapidly changing landscape of the industry.
The 3rd Due Diligence Summit for Life Sciences will provide an overview of the proven strategies and insights of due diligence leaders from medical device, biotechnology and pharmaceutical companies and discuss how best to maneuver the rapidly changing landscape of the industry.
